drugset / Trial / NCT01229254
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to optimize drug exposure in the target population.
Timeline
- Start
- 2010-09
- Primary completion
- 2010-12
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Betrixaban | Small molecule | 30 mg | — |
| Subject | Betrixaban | Small molecule | 60 mg | — |
| Subject | Betrixaban | Small molecule | 90 mg | — |
| Background | Amiodarone | Small molecule | — | — |